Oncology Central

Cause of resistance to olaparib and other PARP inhibitors identified

A team of scientists have identified a mutation in the PARP1 protein that prevents PARP inhibitors, such as olaparib and talazoparib, from working. The findings, published recently in Nature Communications, were obtained by a team from The Institute of Cancer Research (London, UK).
Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.